We have located links that may give you full text access.
Full-Thickness Macular Hole Closure with Topical Medical Therapy.
Retina 2023 November 8
PURPOSE: To examine the efficacy and clinical characteristics of successful full-thickness macular hole (FTMH) closure with topical therapy.
METHODS: Retrospective case series of FTMHs managed by a single retinal physician (DS) diagnosed and treated from 2017-22.
RESULTS: Of 168 patients with FTMHs, 71 patients were started on steroid, carbonic anhydrase inhibitor (CAI), and non-steroidal anti-inflammatory (NSAID) drops. 49 patients (mean 67yrs, 59% women) were included in the analysis; 22 were excluded for poor follow-up. 7/49 were secondary post-PPV holes and 42/49 were idiopathic. 18/49 eyes (36.7%) achieved closure on topical therapy, of which 13 were idiopathic. Hole size was directly correlated with odds of closure: for every 10-micron decrease in size, odds of closure increased by 1.2x (p=0.001, CI 1.1-1.4). Average time to closure was 107.2 days (range 20-512 days), and was not correlated to hole size (p=0.217, CI -0.478-+1.938). The presence of VMT was found to be inversely related to successful closure (OR 6.1, p=0.029, CI 1.2-31.3). There was no significant difference in final BCVA for eyes undergoing primary PPV versus those trialing drops before undergoing PPV (p=0.318, CI -0.094-+0.112).
CONCLUSION: In the first study to-date to report the overall efficacy and clinical characteristics of successful macular hole closure with topical therapy, drops achieved an overall closure rate of 36.7%, with higher efficacy in smaller holes and those without VMT. Rates of MH narrowing and reduction in CFT acted as predictors of effectiveness of drop therapy.
METHODS: Retrospective case series of FTMHs managed by a single retinal physician (DS) diagnosed and treated from 2017-22.
RESULTS: Of 168 patients with FTMHs, 71 patients were started on steroid, carbonic anhydrase inhibitor (CAI), and non-steroidal anti-inflammatory (NSAID) drops. 49 patients (mean 67yrs, 59% women) were included in the analysis; 22 were excluded for poor follow-up. 7/49 were secondary post-PPV holes and 42/49 were idiopathic. 18/49 eyes (36.7%) achieved closure on topical therapy, of which 13 were idiopathic. Hole size was directly correlated with odds of closure: for every 10-micron decrease in size, odds of closure increased by 1.2x (p=0.001, CI 1.1-1.4). Average time to closure was 107.2 days (range 20-512 days), and was not correlated to hole size (p=0.217, CI -0.478-+1.938). The presence of VMT was found to be inversely related to successful closure (OR 6.1, p=0.029, CI 1.2-31.3). There was no significant difference in final BCVA for eyes undergoing primary PPV versus those trialing drops before undergoing PPV (p=0.318, CI -0.094-+0.112).
CONCLUSION: In the first study to-date to report the overall efficacy and clinical characteristics of successful macular hole closure with topical therapy, drops achieved an overall closure rate of 36.7%, with higher efficacy in smaller holes and those without VMT. Rates of MH narrowing and reduction in CFT acted as predictors of effectiveness of drop therapy.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app